Sankyo Co., Ltd. engages in the research, development, manufacture, and marketing of pharmaceutical products primarily in Japan and North America. Its products primarily include Mevalotin, an orally administered anti-hyperlipidemic or cholesterol lowering agent; and Olmesartan, an orally administered anti-hypertension agent marketed in the United States under the brand name Benicar, and in Europe and Japan under the brand name Olmetec. The company also offers Loxonin, an orally administered nonsteroidal analgesic and anti-inflammatory agent that is distributed directly in Japan and other markets, and through its subsidiaries and third party distributors in South America and other markets. In addition, it provides Banan, an oral antibiotic agent, which is distributed directly in Japan, and distributed outside Japan through its subsidiaries and third party licensees. Further, the company has marketing rights pursuant to licensing agreements for various products, which include Venofer, Kremezin, WelChol, and Zantac. Additionally, Sankyo has various products in the preclinical and clinical stage of development. The company also provides food products; additives and agrochemical products, such as insecticides, fungicides, and herbicides; chemical products; and veterinary drugs and feed. Sankyo was founded in 1899 under the name Sankyo Shoten and changed its name to Sankyo Co., Ltd. in 1913. The company is headquartered in Tokyo, Japan.